Compare NL & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NL | SLN |
|---|---|---|
| Founded | 1891 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.9M | 318.4M |
| IPO Year | N/A | N/A |
| Metric | NL | SLN |
|---|---|---|
| Price | $5.79 | $6.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $39.67 |
| AVG Volume (30 Days) | 26.8K | ★ 317.2K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $159,004,000.00 | $25,830,000.00 |
| Revenue This Year | $15.75 | N/A |
| Revenue Next Year | $2.44 | N/A |
| P/E Ratio | $29.02 | ★ N/A |
| Revenue Growth | 5.52 | ★ 40.39 |
| 52 Week Low | $5.04 | $1.97 |
| 52 Week High | $9.27 | $8.08 |
| Indicator | NL | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 45.38 |
| Support Level | $5.42 | $6.12 |
| Resistance Level | $5.74 | $6.72 |
| Average True Range (ATR) | 0.24 | 0.51 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 79.46 | 17.96 |
NL Industries Inc is a holding company that operates in the component products industry. Through its subsidiary, it manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. It also produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.